Although treatment of Alzheimer’s disease using osmotin is still being researched, some small-molecule inhibitors of SREBP2 have been developed and demonstrate promising results in decreasing cholesterol levels. Here, SREBF2 is linked to early-onset autosomal dominant Alzheimer disease.